Alum application to improve water quality in a municipal wastewater treatment wetland: effects on macrophyte growth and nutrient uptake.

Application of low doses of alum to treatment wetlands to reduce elevated outflow winter phosphorus concentrations were tested in mesocosms vegetated with either Typhadomingensis, Schoenoplectus californicus, or submerged aquatic vegetation (SAV) (Najas guadalupensis-dominated). Alum was pumped to experimental units at a rate of 0.91 g Al m(-2) d(-1) and water quality monitored for 3 months. The alum application significantly improved the outflow water quality and overall the growth of the plants was unaffected by the alum application. Biomass and growth varied between species and through time, but no significant effects of alum application were detected. The concentrations of nutrients and mineral elements in the aboveground tissues differed between species and over time, but only the concentration of Al in plant tissue was increased by alum additions. The concentration of Al was 50-fold higher in alum-treated SAV as compared to the control, and in Typha and Schoenoplectus the concentrations were 4- and 2-fold, higher, respectively. The N/P ratios in the plant tissues were low (<10) suggesting that their growth and biomass was limited by nitrogen. The research suggests that a continuous or seasonal low-dosage alum application to treatment wetlands provides an effective tool to maintain discharge concentrations within permitted values during the inefficient winter treatment times. We suggest that the use of alum should be restricted to treatment wetland areas dominated by emergent vegetation as the effects of the elevated Al concentrations in SAV needs further study.

Mechanism of action of clinically approved adjuvants.

Aluminum-containing adjuvants continue to be the most widely used adjuvants for human use. In the last year a major breakthrough has been the realization that alum adjuvant triggers an ancient pathway of innate recognition of crystals in monocytes and triggers them to become immunogenic dendritic cells, nature's adjuvant. This recognition can occur directly, via the triggering of the NALP3 inflammasome by alum crystals, or indirectly through release of the endogenous danger signal uric acid. It is also clear now that adjuvants trigger the stromal cells at the site of injection, leading to the necessary chemokines that attract the innate immune cells to the site of injection. How exactly these pathways interact remains to be determined.

Integrated biological and physiochemical treatment process for nitrate and fluoride removal.

The feasibility of an integrated biological and physiochemical water treatment process for nitrate and fluoride removal has been evaluated. It consisted of two sequencing batch reactors (SBRs) in series. Performance of the process in the treatment of 24 synthetic water samples having nitrate concentrations of 40, 80, 120, 160, 200, and 250 mg/l (as N) and fluoride concentrations of 6, 10, 15, and 20 mg/l at different combinations was studied. Denitrification followed by defluoridation proved to be the best sequence of treatment. In all cases nitrate could be reduced to an acceptable level of less than 10 mg/l (as N) at 3, 5, and 7 h hydraulic retention times (HRTs) depending on its initial concentration. Fluoride concentrations up to 15 mg/l associated with nitrate concentrations up to 80 mg/l (as N) could be reduced acceptable 1.5 mg/l by alum-PAC slurry using alum doses up 850 mg/l [as Al2(SO4)3 x 16H2O] along with 100 mg/l of powdered activated carbon (PAC). Additional alkalinity produced during denitrification was used up during defluoridation for maintenance of pH avoiding the need for lime addition. On the other hand, residual organics, turbidity, and sulfide present in the denitrified water are removed by alum and PAC at the defluoridation stage along with fluoride, eliminating the need for an additional post-treatment step. At higher nitrate concentrations (> or = 120 mg/l as N), the alkalinity produced at the denitrification stage was in the range of 715-1175 mg/l as CaCO3. This excessive alkalinity inhibited reduction of fluoride to the level of 1.5 mg/l at the defluoridation stage, using alum doses up to 900 mg/l along with 100 mg/l of PAC. In all cases a fluoride concentration of 20 mg/l in water could not be reduced to the acceptable level of 1.5 mg/l.

Immunotherapy with an alum-adsorbed Parietaria-pollen allergoid: a 2-year, double-blind, placebo-controlled study.

A double-blind, placebo-controlled study was performed in order to confirm the safety, suitability, and efficacy of an alum-adsorbed Parietaria judaica-pollen allergoid, Allergovit, for allergen-specific immunotherapy. Parietaria pollen is an important cause of pollinosis, particularly in the Mediterranean zone, where it may be encountered for up to 8-9 months of the year. It is an aggressive allergen, and the doses tolerated during immunotherapy are less than those achieved with grass pollen. This factor increases the desirability of using therapeutic preparations with minimal IgE-binding activity, such as allergoids, in order to reduce the risk of side-effects and enable patients to tolerate a higher dose of allergen, thereby increasing the chances of successful specific immunotherapy. Forty patients with rhinitis and/or asthma were allocated at random to active- or placebo-treatment groups at the beginning of the study. All patients received the active preparation during the second year of the study. Immunotherapy was well tolerated by all patients and the incidence of side-effects was low. Treatment resulted in significant reductions in specific cutaneous reactivity and increases in nasal tolerance. A progressive improvement in nasal inspiratory peak flow in association with the immunotherapy indicated a reduction in nasal inflammation. These objective assessments of efficacy endorsed the results from the patients' diary cards, which indicated significant improvements in symptoms and reductions in the use of medication. The immunologic activity of the therapeutic preparation was demonstrated by the induction of a significant specific-IgG antibody response, with increases in IgG4 during the second year of treatment. We conclude that the safety and efficacy of immunotherapy with the Parietaria allergoid make it suitable for consideration in the treatment of patients with Parietaria-pollen-induced rhinitis or asthma.

Evaluation of the toxicity of alum (aluminum sulfate) in young broiler chickens.

Two experiments were conducted to characterize the toxicity and evaluate the efficacy of alum to increase intestinal strength in young broiler chicks. Cobb x Cobb male broiler chicks were placed in an experimental design consisting of six dietary treatments of alum (control, 0.23, 0.47, 0.93, 1.9, and 3.7%) with four replicate pens of 10 broilers per pen. The chicks were housed in electrically heated batteries and provided the treatments for ad libitum consumption from 1 d to 3 wk of age. Alum significantly (P < or = 0.05) decreased body weights at 1.9 and 3.7% in Experiment 1 and at 0.93, 1.9, and 3.7% in Experiment 2. Feed conversion and the relative weight of the gizzard were increased in both experiments at 3.7%. Serum phosphorus was decreased at 1.9 and 3.7% in Experiment 1 and at 3.7% in Experiment 2. Intestinal and bone strength were decreased in both experiments at 3.7%. Bone ash was reduced at 3.7% in Experiment 2, bone S levels increased at 1.9 and 3.7% in Experiment 1 and at 3.7% in Experiment 2, and bone Al levels were elevated in both experiments at 3.7%. Muscle levels of P and S decreased, and that of Ca increased at 3.7%. Aluminum levels were not elevated in muscle tissues. These data indicate that alum can be toxic to young broiler chicks, but at levels that would not be expected to be reached through litter consumption, and that alum did not increase intestinal strength.

Immunoadjuvant action of liposomes: comparison with other adjuvants.

Dehydration-rehydration vesicles (DRV liposomes) composed of equimolar phospholipid and cholesterol and containing bovine serum albumin (BSA) were used together with free BSA to immunize Balb/C mice. Primary and secondary immune responses (IgG1) to the liposomal antigen, as measured by ELISA in mouse sera, were similar for egg phosphatidylcholine (PC) and distearoyl phosphatidylcholine (DSPC) DRV, and much greater than those elicited by free BSA. The adjuvanticity of PC DRV was compared with that of aluminium salts (alum), complete Freund's adjuvant (CFA) and N-acetyl muramyl-L-threonyl-D-isoglutamine ([Thr1]MDP), the latter used as such or in a liposome form co-entrapped with the antigen. DRV (with or without co-entrapped [Thr1]MDP), and alum were equally strong in producing primary and secondary immune responses (IgG1) to BSA. Such responses were significantly higher than those achieved with CFA and [Thr1]MDP alone. The implications of these results for the potential role of liposomes as immunological adjuvants in vaccines are discussed.